menu
    • menu
    [{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"FXR314","moa":"FXR","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Eli Lilly"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Organovo Holdings \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Organovo Holdings

    Menu

    Organovo Holdings

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Organovo Holdings

                            U.S.A arrow
                            Excipient World
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Excipient World
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Pays $10M Upfront for Organovo’s FXR Agonist Program

                            Details : Through the acquisition, Lilly will leverage FXR program of Organovo, which includes FXR314, it is being evaluated for the treatment of Inflammatory Bowel Disease.

                            Product Name : FXR314

                            Product Type : Other Small Molecule

                            Upfront Cash : $10.0 million

                            February 25, 2025

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Organovo Holdings

                            U.S.A arrow
                            Excipient World
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Excipient World
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Jonestrading Institutional Services

                            Deal Size : $5.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

                            Details : Proceeds will advance the company's pipeline, including lead molecule FXR314, targeting inflammatory bowel disease and applications in metabolic liver disease.

                            Product Name : FXR314

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : FXR314

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Jonestrading Institutional Services

                            Deal Size : $5.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Organovo Holdings

                            U.S.A arrow
                            Excipient World
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Excipient World
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Organovo Reveals Positive Phase 2 Results for FXR314 in MASH

                            Details : The company’s lead molecule, FXR314, the non-steroidal, non-bile acid FXR agonist, is being developed for the treatment of metabolic function-associated steatohepatitis (MASH).

                            Product Name : FXR314

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 15, 2024

                            Lead Product(s) : FXR314

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Organovo Holdings

                            U.S.A arrow
                            Excipient World
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Excipient World
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

                            Details : FXR314, an FXR agonist, has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in ulcerative col...

                            Product Name : FXR314

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 23, 2023

                            Lead Product(s) : FXR314

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth